Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. More Details
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has Alnylam Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALNY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ALNY's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ALNY underperformed the US Biotechs industry which returned 22.3% over the past year.
Return vs Market: ALNY underperformed the US Market which returned 53.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Alnylam Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StCan You Imagine How Alnylam Pharmaceuticals' (NASDAQ:ALNY) Shareholders Feel About The 95% Share Price Increase?
1 month ago | Simply Wall StIs Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
1 month ago | Simply Wall StIs There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 47% Undervaluation?
Is Alnylam Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALNY ($138.88) is trading below our estimate of fair value ($252.18)
Significantly Below Fair Value: ALNY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALNY is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALNY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALNY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALNY is overvalued based on its PB Ratio (15.9x) compared to the US Biotechs industry average (3.7x).
How is Alnylam Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALNY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ALNY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALNY's is expected to become profitable in the next 3 years.
Revenue vs Market: ALNY's revenue (32.1% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ALNY's revenue (32.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALNY's Return on Equity is forecast to be high in 3 years time (29%)
How has Alnylam Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALNY is currently unprofitable.
Growing Profit Margin: ALNY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALNY is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.
Accelerating Growth: Unable to compare ALNY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALNY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: ALNY has a negative Return on Equity (-84.46%), as it is currently unprofitable.
How is Alnylam Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ALNY's short term assets ($2.6B) exceed its short term liabilities ($585.3M).
Long Term Liabilities: ALNY's short term assets ($2.6B) exceed its long term liabilities ($1.8B).
Debt to Equity History and Analysis
Debt Level: ALNY's debt to equity ratio (18.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ALNY's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALNY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALNY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Alnylam Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALNY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALNY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALNY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALNY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALNY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Maraganore (57 yo)
Dr. John M. Maraganore, M.D., Ph.D. serves as a Senior Advisor at General Atlantic Service Company, L.P., providing strategic support and advice to the firm’s investment teams and portfolio companies in th...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD7.82M) is about average for companies of similar size in the US market ($USD11.15M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: ALNY's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: ALNY's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.
Alnylam Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Alnylam Pharmaceuticals, Inc.
- Ticker: ALNY
- Exchange: NasdaqGS
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.120b
- Shares outstanding: 117.32m
- Website: https://www.alnylam.com
Number of Employees
- Alnylam Pharmaceuticals, Inc.
- 675 West Kendall Street
- Henri A. Termeer Square
- United States
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi ther...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/20 00:01|
|End of Day Share Price||2021/04/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.